Hanmi Science Co Ltd
KRX:008930
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
26 750
56 200
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Hanmi Science Co Ltd
Hanmi Science Co Ltd
Total Current Liabilities
Hanmi Science Co Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hanmi Science Co Ltd
KRX:008930
|
Total Current Liabilities
₩426.8B
|
CAGR 3-Years
26%
|
CAGR 5-Years
14%
|
CAGR 10-Years
4%
|
|
|
Yuhan Corp
KRX:000100
|
Total Current Liabilities
₩570.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
10%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Total Current Liabilities
₩241.6B
|
CAGR 3-Years
51%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Total Current Liabilities
₩678.1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
15%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Total Current Liabilities
₩58.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Total Current Liabilities
₩237.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
Hanmi Science Co Ltd
Glance View
Hanmi Science Co., Ltd. engages in the management of its subsidiaries. The company is headquartered in Hwaseong, Gyeonggi-Do. Through subsidiaries in Japan, Europe and Korea, the Company operates in three segments. The Pharmaceutical Products Wholesale segment mainly engages in the distribution of pharmaceutical products. The Holding Business segment mainly engages in the business of controlling subsidiaries. The Other segment mainly engage in the production and sales of pharmaceuticals, and the supply of quasi-drugs and health functional foods, beverages and functional cosmetics.
See Also
What is Hanmi Science Co Ltd's Total Current Liabilities?
Total Current Liabilities
426.8B
KRW
Based on the financial report for Sep 30, 2024, Hanmi Science Co Ltd's Total Current Liabilities amounts to 426.8B KRW.
What is Hanmi Science Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
4%
Over the last year, the Total Current Liabilities growth was 36%. The average annual Total Current Liabilities growth rates for Hanmi Science Co Ltd have been 26% over the past three years , 14% over the past five years , and 4% over the past ten years .
You don't have any saved screeners yet
